

Arik Ben Dor +1 212 526 7713 arik.bendor@barclays.com BCI, US

Jingling Guan +1 212 526 3623 jingling.guan@barclays.com BCI, US

Fallen Angel Strategy Performance – An Update

Americas Advisory Council
June 2018

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report.

The Downgrade Dynamics of IG to HY Bonds (Fallen Angels)

- Most investors are required to sell
- Selling takes place over a short window



❖IG bonds are larger than HY bonds, on average





The selling imbalance leads to excessive declines in fallen angels' bond prices followed by strong mean-reversion




Excessive Declines Followed by Mean-Reversion in Prices

- Ben Dor and Xu (2010 Link to report)
- Fallen angels (FA) underperformed IG peers by 15.1% in the downgrade month and preceding year
- Outperformed IG and HY peers by 10.2% and 6.3% over the next two years, respectively
- Reversal is limited to bonds. FA equities continue to underperform

FA Performance Around Downgrade Month

FA Performance: Bonds Vs. Equities

Based on Monthly Observations January 1990 – June 2010



Note: Returns computed using value weighting. Source: Compustat, Barclays Research



Performance Update



Fallen Angel Reversal (FAR): Rule-based Fallen Angel Strategy


Original study has two portfolios: 'Buy All' and '3-Month Reversal' - all invest solely in fallen angels


	FA Strategy Bond Inclusion/Exclusion Criteria				
		Buy All	3-Month Reversal (FAR)		
Buy Conditions	Timing	Downgrade Month	Month 3		
(if all are satisfied)	Spread relative to Peers	N/A	>= 40 bps		
	Bond Price	N/A	>=40		
Sell Triggers	Timing	Month 24	Month 24		
(if any one is	Spread relative to Peers	N/A	Negative		
satisfied)	Technical	Bonds matured, defaulted or were called			

Source: Barclays Research

- Fully seeded with cash at inception, rebalanced monthly
- One bond per issuer with a 10% issuer limit
- Unallocated capital invested in peer benchmark
- Equally weighted positions

Example







Restricted - External

5

14 June 2018

FAR Stayed Profitable Over Time

■ FAR strategy still outperformed peers and had similar inf. ratios over the peer group in the recent period (January 2015 to April 2018)

The Performance of FAR Portfolios ('3-Month Reversal')						
	FAR Portfolio	Peer Group	Ret. over Peer Group	High-Yield Index	Ret. over HY Index	
Jan. 1991 - Jun. 2010 (Ben Dor and Xu 2010	study)					
Average (Monthly)	1.62%	0.84%	0.78%	0.81%	0.82%	
Volatility (Monthly)	3.99%	2.31%	2.63%	2.68%	2.56%	
Sharpe/Inf. Ratio (Ann.)	1.12	0.76	1.03	0.61	1.11	
% of Positive Ret. Months	75%	76%	63%	76%	64%	
% Invested in Fallen Angels	69%					
Jul. 2010 - Dec. 2014 (Ben Dor and Xu 2015	update)					
Average (Monthly)	1.11%	0.80%	0.31%	0.74%	0.38%	
Volatility (Monthly)	1.85%	1.62%	0.88%	1.78%	0.92%	
Sharpe/Inf. Ratio (Ann.)	2.06	1.67	1.23	1.40	1.42	
% of Positive Ret. Months	74%	74%	65%	74%	70%	
% Invested in Fallen Angels	55%					
Jan. 2015 - Apr. 2018						
Average (Monthly)	1.02%	0.42%	0.60%	0.47%	0.55%	
Volatility (Monthly)	2.97%	1.59%	1.75%	1.57%	1.68%	
Sharpe/Inf. Ratio (Ann.)	1.12	0.80	1.19	0.91	1.14	
% of Positive Ret. Months	63%	70%	63%	65%	60%	
% Invested in Fallen Angels	91%					


Note: The returns for the portfolios' peer group were computed as the equal—weighted performances of the individual bonds' peer groups. Sharpe Ratio was calculated using 1m Libor. Inf. ratio is the ratio of average and standard deviation of relative returns. Source: Barclays Research



FAR Delivered Persistent Outperformance Over Time

- Since the publication of our original study in 2010, FAR has consistently delivered outperformed over peers and HY indices
- There is no decaying of outperformance in recent years

Cumulative Returns of FAR Portfolios (June 2010 – April 2018)



Source: Barclays Research



FAR Had Persistent Outperformance in European Markets

 FAR strategy had persistent returns in European markets, even after publication of our 2010 paper and 2015 update

Performance of FAR strategy in European Markets						
	FAR Portfolio	Peer Group	Ret. over Peer Group	High-Yield Index	FAR - HY Index	
Jan. 199	or and Xu 201	0)				
Average (Monthly)	0.73%	0.33%	0.40%	0.48%	0.25%	
Volatility (Monthly)	4.63%	3.89%	1.86%	4.01%	1.90%	
Sharpe/Inf. Ratio (Ann.)	0.34	0.05	0.74	0.18	0.46	
% of Positive Ret. Months	63%	66%	46%	67%	47%	
% Invested in Fallen Angels	21.16%					
Jul. 2010	0 - Dec. 2014	(Ben Dor and 2	Xu 2015 updat	te)		
Average (Monthly)	1.36%	0.80%	0.56%	0.85%	0.51%	
Volatility (Monthly)	5.20%	3.25%	2.89%	2.44%	3.31%	
Sharpe/Inf. Ratio (Ann.)	0.89	0.84	0.67	1.18	0.53	
% of Positive Ret. Months	78%	78%	70%	76%	72%	
% Invested in Fallen Angels	85.19%					
Jan. 2015 - Apr. 2018						
Average (Monthly)	0.68%	0.38%	0.30%	0.42%	0.26%	
Volatility (Monthly)	1.75%	1.00%	0.92%	1.27%	0.74%	
Sharpe/Inf. Ratio (Ann.)	1.24	1.12	1.13	0.99	1.22	
% of Positive Ret. Months	68%	60%	60%	63%	60%	
% Invested in Fallen Angels	46.75%					


Note: The returns for the portfolios' peer group were computed as the equal—weighted performances of the individual bonds' peer groups. Sharpe Ratio was calculated using 1m Libor. Inf. ratio is the ratio of average and standard deviation of relative returns. Source: Barclays Research



More than 80% of FAR Bonds Outperformed Peers

- In the cross-section, more than 80% of the FAR constituents had higher returns over their peer groups during their holding period
- Similar distribution in the US and Europe

Cumulative Distribution of Pair-Wise FAR Return over Peer Group (US: Jan. 1991 – Apr. 2018; Euro: Jan. 1999 – Apr. 2018)




Source: Barclays Research



FAR Portfolio Had Similar Characteristics vs. Peers


- FAR Constituents had very similar size, maturity, rating, and LCS as peers, indicating that FAR's outperformance was not driven by difference in characteristics
- European FAR constituents also had similar characteristics as peers and indices





FAR Industry Composition Different from Index's

- Historically, FAR portfolios were weighted more heavily in financials and utilities compared with the HY index, and underweighted in some other industries
- The overweight/underweight was due to these industries having more/fewer downgrades, and not because of any systematic bias in the strategy (the spread triggers are relative to peers in the same industry)
- The overweight/underweight could change drastically from month to month as new fallen angels enter the FAR portfolio






11

14 June 2018

Similar Industry Pattern in Euro FAR Historically

- Historically, Euro FAR industry composition had similar patterns vs. the index
- The overweight/underweight also changed drastically from month to month

Industry Composition of FAR Portfolios (Euro)





Additional Aspects of Fallen Angel Strategies



How did 'Buy All' Strategy do Out-of-Sample?

- Since original publication in 2010, 'Buy All' strategy fared poorly from 2010-14, and very well since 2015 (but still did not outperform '3m Reversal' strategy)
- 'Buy All' did not display the same consistent performance as '3m Reversal'

Performance of Fallen Angel '3m Reversal' vs. 'Buy All' Strategies

	3m Reversal (FAR)				Buy All					
	FAR Portfolio	Peer Group	Ret. over Peer Group	High- Yield Index	Ret. over HY Index	FAR Portfolio	Peer Group	Ret. over Peer Group	High- Yield Index	Ret. over HY Index
Jan. 1991 - Jun. 2010 (Ben Dor	Jan. 1991 - Jun. 2010 (Ben Dor and Xu 2010 study)									
Average (Monthly)	1.62%	0.84%	0.78%	0.81%	0.82%	1.07%	0.76%	0.31%	0.81%	0.26%
Volatility (Monthly)	3.99%	2.31%	2.63%	2.68%	2.56%	2.79%	2.16%	1.68%	2.68%	1.84%
Sharpe/Inf. Ratio (Ann.)	1.12	0.76	1.03	0.61	1.11	0.90	0.68	0.64	0.61	0.50
% of Positive Ret. Months	75%	76%	63%	76%	64%	73%	75%	58%	76%	57%
% Invested in Fallen Angels	69%					98%				
Jul. 2010 - Dec. 2014 (Ben Dor and Xu 2015 update)										
Average (Monthly)	1.11%	0.80%	0.31%	0.74%	0.38%	0.78%	0.75%	0.03%	0.74%	0.05%
Volatility (Monthly)	1.85%	1.62%	0.88%	1.78%	0.92%	1.67%	1.65%	0.84%	1.78%	0.90%
Sharpe/Inf. Ratio (Ann.)	2.06	1.67	1.23	1.40	1.42	1.59	1.54	0.14	1.40	0.18
% of Positive Ret. Months	74%	74%	65%	74%	70%	76%	74%	59%	74%	61%
% Invested in Fallen Angels	55%					100%				
Jan. 2015 - Apr. 2018										
Average (Monthly)	1.02%	0.42%	0.60%	0.47%	0.55%	0.96%	0.49%	0.47%	0.47%	0.49%
Volatility (Monthly)	2.97%	1.59%	1.75%	1.57%	1.68%	3.08%	1.69%	1.78%	1.57%	1.94%
Sharpe/Inf. Ratio (Ann.)	1.12	0.80	1.19	0.91	1.14	1.01	0.88	0.91	0.91	0.87
% of Positive Ret. Months	63%	70%	63%	65%	60%	65%	68%	58%	65%	60%
% Invested in Fallen Angels	91%					96%				




Restricted - External

Why did 'Buy All' Strategy Do Well since 2015?

- In recent years, fallen angel price reversal happened at a much faster speed than historically
- 'Buy All' strategy included fallen angels into the portfolio immediately after their downgrades. Capturing the initial price reversal improved its performance

Cumulative Ret. vs. Peers around Downgrade Month (EW)








FAR Demonstrates Stability over Choice of Inclusion Months

- For 'Buy All' strategy, it was optimal to wait three months historically, but optimal to include immediately in recent periods
- As a comparison, FAR strategy demonstrates stability over different periods regarding inclusion month

Inf. Ratio of FA over Peer Ret. with diff. Inclusion Months, '3m Reversal' vs. 'Buy All'





Restricted - External

16 14 June 2018

Additional Aspects on Fallen Angel Strategies

Profits insensitive to changes in key parameters

Changing the position limit from 10% to 5% and min. relative spreads from 40bp to 20bp had very limited effect on strategy performance

FAR Strategy is a fallen angel strategy, not a general mean-reversion strategy

The "3M Reversal" strategy using HY bonds that are not fallen angels underperformed the FA "3m Reversal" strategy

Default rate of fallen angels is not higher than other HY bonds

Net performance remains attractive after using LCS as estimates of transaction cost

FAR S.R. remains strong even for large portfolios

The decline in performance is partially offset by lower risk as cash position increases



Key Takeaways



Summary

Key takeaways

- ✓ FAR continued to deliver similar outperformance after initial publication.
- ✓ FAR strategy works in Europe as well
- ✓ The outperformance of fallen angels over peers is present in more than 80% of the sample
- ✓ FAR had similar characteristics as peers not a source of its outperformance
- ✓ FAR strategy demonstrates stability in terms of choice of inclusion months and other key parameters

Extensions

Using initial price decline as trigger for inclusion,	and subsequent outperformance as
signal to close the trade	

- ☐ Using LCS and bond turnover as additional signal for trade
- ☐ Using cash/CDS basis as selection criteria



Analyst Certifications and Important Disclosures

Analyst Certification(s)

We, Arik BenDor and Jingling Guan, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the assect class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research, whether as a result of differing time horiz

The Barclays Research Department operates independently from the Absa Research Department. Absa Research is produced by Absa Bank Limited acting through its Corporate and Investment Bank division, which is a part of Barclays Africa Group Limited and affiliated with the Investment Bank of Barclays Bank PLC. Eligible clients may receive research reports from both research departments, which may reach different conclusions and may contain different and conflicting forecasts, recommendations, or trade ideas. In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

All pricing information is indicative only. Prices are sourced from Thomson Reuters as of the last available closing price at the time of production of the research report, unless another time and source is indicated.

Explanation of other types of investment recommendations produced by Barclays FICC Research:

Trade ideas contained herein that have been produced by the Credit teams within Barclays Research are valid at current market conditions and may not be otherwise relied upon.

Trade ideas contained herein that have been produced by other research teams within Barclays FICC Research shall remain open until they are subsequently amended or closed in a future research report.

Disclosure of previous investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view previous investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.



Important Disclosures Continued

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)



Disclaimer

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, regulatory and academic organisations for informational purposes and not for the purpose of making investment decisions regarding any debt securities. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC Paris Branch (registered in France under Paris BCS number 381,066,281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudei

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

Subject to the conditions of this publication as set out above, Absa Bank Limited, acting through its Corporate and Investment Bank division, which is a part of Barclays Africa Group Limited and affiliated with the Investment Bank of Barclays Bank PLC, an authorised financial services provider (Registration No.: 1986/004794/06. Registered Credit Provider Reg No NCRCP7), is distributing this material in South Africa. Absa Bank Limited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Absa Bank Limited acting through its Corporate and Investment Bank division in South Africa, 7th Floor, Barclays Towers West, 15 Troye Street, Johannesburg. Absa Bank Limited is an affiliate of the Barclays group.

All Barclays research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.



Disclaimer (continued)

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INB100000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by either Barclays Bank PLC, Barclays Capital Inc., Barclays Capital Securities Limited or Barclays Capital Asia Limited. None of Barclays Bank PLC, nor any of the other referenced Barclays group entities, hold an Australian financial services licence and instead they each rely on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2018). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon reguest. US34347

BRCF2242

